HIV

Know HIV for No HIV? Just check out the facts below to stay safe Forever!

Healthcare Pharmaceuticals

May 18 marks the National HIV Vaccine Awareness Day, so as to acknowledge the people working relentlessly towards devising a vaccine for HIV. In other words, the day sends a gentle reminder regarding research conducted pertaining to HIV vaccine.

An Incurable Disease?

It is a well-known fact that AIDS comes across as an incurable ailment. The basic objective behind celebrating National HIV Vaccine Awareness Day is that of ascertaining that people go for precautionary measures for preventing spread of HIV. The day is also important as it’s an opportunity for extending support to HIV-positive patients.

The Aurum Institute has partnered with International AIDS Vaccine Initiative (IAVI) to unleash new-fangled research on HIV vaccines.

Several community members, volunteers, scientists, and health professionals are being recognized as they are being working together for finding an effective and a safe vaccine to keep HIV at bay.

Trevor Beattie, head of the department of clinical research development projects of Aurum Institute, has gone on records to state that this institute does operate in 5 locations all around South Africa; namely Klerksdorp, Pretoria, Durban, Rustenburg, and Tembisa. Beattie has also given an overview of Aurum Institute’s task on preventing and treating tuberculosis, certain other non-communicable diseases, and Covid-19.

Furthermore, he stated that every clinical site comprised an advisory committee acting as bridge between the researchers and communities. This thus facilitated better understanding and communication regarding trials and research being done. Amongst the 5 mentioned above, the biggest clinical research site is at Tembisa. The site is at the forefront regarding TB-oriented research as well.

Extensive Research

Ansuya Naidoo, medical director at IAVI, is working on IAVI G003 – the HIV germline that is targeting the first study conducted on humans in the US. IAVI is trying to streamline this study in Africa. This process is inclusive of guiding immune system step after step for inducing antibodies to counteract HIV. This study is being funded by none other than The Bill & Melinda Gates Foundation.

Naidoo has extended the point by stating that IAVI wanted to build as well as prepare capacity of research sites in Africa for conducting medical trials for HIV immunogen. She also said that region-specific environmental conditions affecting African people were taken into consideration, which included pollution, climate, nutrition, and the other diseases faced by people. This could, in turn, adversely affect potential vaccine’s efficacy.

Naidoo inferred that the study was in its nascent stage. Though it’s a known reality that HIV is much different as compared to the other courses of ailment and people need to be well-aware of HIV’s sub-types and upcoming treatment-assistant strains and also the strains dominating specific regions or countries.

Naidoo is further emphasizing on conducting study including HIV-negative people as well, as it’s always better to be safe than sorry. Internal support systems are helping in upskilling the medical research systems at the sites identified in Africa. Monitoring would happen for a period of 6 months. For this, of course, consent from participants is needed.

So, as of now, it’s “Prevention is better than Cure” thing.

Leave a Reply

Your email address will not be published.